The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

This randomized phase III trial studies how well Lactobacillus plantarum works in preventing acute graft versus host disease in children undergoing donor stem cell transplant. Lactobacillus plantarum may help prevent the development of gastrointestinal graft versus host disease in children, adolescents, and young adults undergoing donor stem cell transplant.

Start Date30 Apr 2018

Sponsor / Collaborator

The Children's Oncology Group Foundation, Inc.

[+1]

100 Clinical Results associated with Lactobacillus plantarum strain 299

100 Translational Medicine associated with Lactobacillus plantarum strain 299

100 Patents (Medical) associated with Lactobacillus plantarum strain 299

Literatures (Medical) associated with Lactobacillus plantarum strain 299

01 Jan 2025·Journal of Affective Disorders

Probiotic Lactobacillus plantarum 299v supplementation in patients with major depression in a double-blind, randomized, placebo-controlled trial: A metabolomics study

Article

Author: Godzien, Joanna ; Waszkiewicz, Napoleon ; Lopez-Gonzalvez, Angeles ; Szulc, Agata ; Ostrowska, Lucyna ; Barbas-Bernardos, Cecilia ; Barbas, Coral ; Swieton, Justyna ; García, Antonia ; Bernardos, Cecilia Barbas ; Kalaska, Bartlomiej ; Ciborowski, Michal ; Kretowski, Adam ; Rudzki, Leszek ; Pawlak, Dariusz

BACKGROUNDUnderstanding the multifactorial nature of major depressive disorder (MDD) is crucial for tailoring treatments. However, the complex interplay of various factors underlying the development and progression of MDD poses significant challenges. Our previous study demonstrated improvements in cognitive functions in MDD patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) supplemented with Lactobacillus plantarum 299v (LP299v).METHODSTo elucidate the biochemical mechanisms underlying cognitive functions improvements, we explored underlying metabolic changes. We employed multi-platform metabolomics, including LC-QTOF-MS and CE-TOF-MS profiling, alongside chiral LC-QqQ-MS analysis for amino acids.RESULTSSupplementation of SSRI treatment with LP299v intensified the reduction of long-chain acylcarnitines, potentially indicating improved mitochondrial function. LP299v supplementation reduced N-acyl taurines more than four times compared to the placebo, suggesting a substantial impact on restoring biochemical balance. The LP299v-supplemented group showed increased levels of oxidized glycerophosphocholine (oxPC). Additionally, LP299v supplementation led to higher levels of sphingomyelins, L-histidine, D-valine, and p-cresol.LIMITATIONSThis exploratory study suggests potential metabolic pathways influenced by LP299v supplementation. However, the need for further research hinders the ability to draw definitive conclusions.CONCLUSIONSObserved metabolic changes were linked to mitochondrial dysfunction, inflammation, oxidative stress, and gut microbiota disruption. Despite the subtle nature of this alterations, our research successfully detected these differences and connected them to the metabolic disruptions associated with MDD. Our findings emphasise the intricate relationship between metabolism, gut microbiota, and mental health prompting further research into the mechanisms of action of probiotics in MDD treatment.

01 Aug 2024·Food Chemistry

Production of prebiotic enriched maple syrup through enzymatic conversion of sucrose into fructo-oligosaccharides

Article

Author: Simović, Milica ; Milivojević, Ana ; Veljković, Milica ; Banjanac, Katarina ; Bezbradica, Dejan ; Ćorović, Marija

Maple syrup, a popular natural sweetener has a high content of sucrose, whose consumption is linked to different health issues such as obesity and diabetes. Hence, within this paper, the conversion of sucrose to prebiotics (fructo-oligosaccharides, FOS) was proposed as a promising approach to obtaining a healthier, value-added product. Enzymatic conversion was optimized with respect to key experimental factors, and thereafter derived immobilized preparation of fructosyltransferase (FTase) from Pectinex® Ultra SP-L (FTase-epoxy Purolite, 255 IU/g support) was successfully utilized to produce novel functional product in ten consecutive reaction cycles. The product, obtained under optimal conditions (60 °C, 7.65 IU/mL, 12 h), resulted in 56.0% FOS, 16.7% sucrose, and 27.3% monosaccharides of total carbohydrates, leading to a 1.6-fold reduction in caloric content. The obtained products` prebiotic potential toward the probiotic strain Lactobacillus plantarum 299v was demonstrated. The changes in physico-chemical and sensorial characteristics were esteemed as negligible.

01 Nov 2023·Gastroenterology

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Review

Author: Khasawneh, Mais ; Moayyedi, Paul ; Black, Christopher J ; Goodoory, Vivek C ; Ford, Alexander C ; Quigley, Eamonn M M

BACKGROUND & AIMSSome probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.METHODSMEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.RESULTSWe identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.CONCLUSIONSSome combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.

News (Medical) associated with Lactobacillus plantarum strain 299

10 Aug 2023

·www.prnewswire.com

Hyperbiotics Launches PRO-IBS Support* Premium Precision Probiotic Formula

Unique combination formula designed to effectively stabilize gut discomfort and dysfunction in patients with IBS* MIDDLETOWN, Conn., Aug. 10, 2023 /PRNewswire/ -- Hyperbiotics, a global leader in precision probiotics, today announced the launch of PRO-IBS Support *, an advanced, dual-action synergistic blend of Lactiplantibacillus plantarum 299v and the highly bioavailable Boswellia serrata extract. This unique combination formula was designed to effectively stabilize gut discomfort and dysfunction in patients with IBS, and provide accelerated and prolonged relief from bloating, gas, and irregularity.* Continue Reading Hyperbiotics PRO-IBS Support* Probiotic According to the American College of Gastroenterology, an estimated 10-15% of the adult population in the United States have irritable bowel syndrome (IBS), but only 5-7% receive an IBS diagnosis. PRO-IBS Support* has been uniquely formulated to provide patients with relief from occasional IBS symptoms more quickly, and for prolonged periods of time, while nurturing a healthier gut microbiome. This carefully selected blend of clinically studied ingredients works synergistically to reset and support the gut, promoting improved gut function, regularity, and overall well-being for individuals seeking effective digestive support.* KEY FEATURES Each capsule contains 30 billion CFUs of Lactiplantibacillus plantarum 299v, the clinically effective dose and strain used in over 65 clinical studies Highly bioavailable, lecithin-based Boswellia serrata extract 125mg in a clinically studied dose range with standardized phytoactives Clean formula, and free from major allergens, including gluten, dairy, soy, egg, peanut, tree nut, fish, shellfish, sesame, active yeast, and preservatives No artificial colors, flavors, or sweeteners No unnecessary excipients Suitable for vegans and vegetarians Shelf-Stable Non-GMO "With the prevalence of IBS and related conditions, we saw a critical need to introduce an affordable, science-backed solution for patients," explained John P. Troup, PhD, Chief Science and Education Officer, Hyperbiotics. "By pairing clinically studied Lactiplantibacillus plantarum 299v with Boswellia serrata extract, we are able to offer a dual-action solution that provides more effective relief than standalone probiotics." Hyperbiotics offers a comprehensive line of precision probiotics – harnessing science-backed probiotic strains to deliver probiotics tailored to patient needs, at an affordable price point. Hyperbiotics probiotics are vegan, non-GMO and shelf-stable. To learn more or purchase, visit Hyperbiotics.com/ProIBSSupport. About Hyperbiotics Hyperbiotics is a leading probiotic brand committed to serving the needs of practitioners, their patients, and individuals striving to improve their gut health and overall well-being through targeted precision probiotics. Through the utilization of "precision probiotics" Hyperbiotics harnesses well-researched probiotic strains and complementary ingredients to deliver premium formulas, tailored to specific patient needs, at an affordable price. Hyperbiotics is part of the Blueroot Health family of brands. To learn more, visit Hyperbiotics.com. About Blueroot Health Blueroot Health™ is a consumer health company growing a diverse portfolio of brands that fuel lasting happiness and health for people and planet. The company's industry-leading brands – including  Vital Nutrients®,  Bariatric Fusion®,  Fairhaven Health® and  Hyperbiotics® – offer a suite of clean, innovative, and clinically relevant nutritional supplements that work. The portfolio includes specialized solutions for fertility and reproductive health, metabolic and bariatric health, and precision probiotics, as well as a full spectrum of clinically relevant formulas trusted by healthcare practitioners, patients, and consumers worldwide. Blueroot Health is committed to making a lasting, positive impact on the communities it serves, without leaving a negative footprint on the planet. For more information, visit blueroothealth.co. Media Contact Erin Anthony [email protected] *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. SOURCE Hyperbiotics

100 Deals associated with Lactobacillus plantarum strain 299

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Graft Versus Host Disease	Phase 3	US	National Cancer Institute	30 Apr 2018
Acute Graft Versus Host Disease	Phase 3	CA	National Cancer Institute	30 Apr 2018
Leukemia	Phase 3	CA	National Cancer Institute	30 Apr 2018
Leukemia	Phase 3	US	National Cancer Institute	30 Apr 2018
Lymphoma	Phase 3	US	National Cancer Institute	30 Apr 2018
Lymphoma	Phase 3	CA	National Cancer Institute	30 Apr 2018
Graft vs Host Disease	Phase 3	-	The Children's Oncology Group Foundation, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03057054 (CTgov)	Phase 3	Acute Graft Versus Host Disease \| Leukemia \| Lymphoma	173	Allogeneic Hematopoietic Stem Cell Transplantation+Lactobacillus plantarum strain 299v (Arm I (Lactobacillus Plantarum, alloHCT))	dgyhkfzssb(wnxdoxwkbf) = yhekguqmno tlktvwnrrg (ijawleetpk, jrjrsfebwz - qpvewzoqwi) View more	-	17 Jul 2023
				Allogeneic Hematopoietic Stem Cell Transplantation (Arm II (Placebo, alloHCT))	dgyhkfzssb(wnxdoxwkbf) = etrcbqqhxt tlktvwnrrg (ijawleetpk, rkiewiobun - akjjchyjzw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lactobacillus plantarum strain 299

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation